Prelude Therapeutics Incorporated (PRLD) announced on Tuesday that it has entered into a collaboration with Merck to evaluate the combination of Prelude's PRT3789 and Merck's KEYTRUDA in a Phase 2 clinical study targeting patients with SMARCA4-mutated cancers.
Under the terms of the agreement, Merck will supply KEYTRUDA for the Phase 2 study, which Prelude will sponsor. Both Prelude and Merck will retain all commercial rights to their respective compounds, whether used as monotherapies or in combination therapies.
PRT3789, a leading and highly selective SMARCA2 degrader, is currently undergoing a Phase 1 clinical study involving biomarker-selected patients with SMARCA4 mutations.
